Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers

Pharmacogenetics and Genomics
M DobrinasChin B Eap

Abstract

There is a high interindividual variability in cytochrome P4501A2 (CYP1A2) activity and in its inducibility by smoking, only poorly explained by known CYP1A2 polymorphisms. We aimed to study the contribution of other regulatory pathways, including transcription factors and nuclear receptors, toward this variability. CYP1A2 activity was determined by the paraxanthine/caffeine ratio in 184 smokers and in 113 of them who were abstinent for 4 weeks. Participants were genotyped for 22 polymorphisms in 12 genes. A significant influence on CYP1A2 inducibility was observed for the NR1I3 rs2502815 (P=0.0026), rs4073054 (P=0.029), NR2B1 rs3818740 (P=0.0045), rs3132297 (P=0.036), AhR rs2282885 (P=0.040), rs2066853 (P=0.019), NR1I1 rs2228570 (P=0.037), and NR1I2 rs1523130 (P=0.044) polymorphisms. Among these, the NR1I3 rs2502815 (P=0.0045), rs4073054 (P=0.048), and NR2B1 rs3818740 (P=0.031) also influenced CYP1A2 basal activity. This is the first in-vivo demonstration of the influence of genes involved in CYP1A2 regulatory pathways on its basal activity and inducibility by smoking. These results need to be confirmed by other studies.

References

May 12, 1997·Mutation Research·S MacLeodN P Lang
Sep 6, 2002·Chemico-biological Interactions·Patricia A HarperAllan B Okey
Mar 19, 2004·The Journal of Biological Chemistry·Daniel W NebertFrank J Gonzalez
Jun 23, 2004·Journal of Clinical Psychopharmacology·Chin B EapFranck Broly
Aug 19, 2004·Gene·André G UitterlindenJohannes P T M Van Leeuwen
Apr 26, 2005·Journal of Biochemical and Molecular Toxicology·Marta J NarvaezL C Quattrochi
May 19, 2005·Pharmacogenetics and Genomics·Allan B OkeyPatricia A Harper
Jul 2, 2005·Molecular Genetics and Metabolism·Shinobu IkedaJun-ichi Sawada
Apr 13, 2006·Pharmacogenetics and Genomics·Zhengwen JiangDaniel W Nebert
Sep 8, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lisa A Kroon
Dec 25, 2007·Pharmacogenomics·Jatinder K Lamba
Aug 26, 2009·Geriatrics & Gerontology International·Tomohiko UranoSatoshi Inoue
Nov 26, 2009·The Journal of Pharmacology and Experimental Therapeutics·Vishal LambaErin G Schuetz
May 20, 2011·Clinical Pharmacology and Therapeutics·M DobrinasChin B Eap
Jan 1, 2010·Frontiers in Pharmacology·Kathrin KleinUlrich M Zanger

Citations

Aug 6, 2014·Current Hypertension Reports·Idris GuessousMurielle Bochud
Jan 21, 2016·Expert Opinion on Drug Metabolism & Toxicology·Erika CecchinGiuseppe Toffoli
Jan 1, 2014·Journal of Clinical Pharmacy and Therapeutics·L SongL Wang
Dec 29, 2017·The Pharmacogenomics Journal·N KoonrungsesomboonS Teekachunhatean
Aug 17, 2018·Acta Psychiatrica Scandinavica·M Na TakuathungN Koonrungsesomboon
Sep 9, 2015·Obstetrics and Gynecology·Kacey Y EichelbergerAlison M Stuebe

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.